Nucleic acids have considerable potential as therapeutic agents in the treatment of pathologies including genetic diseases, viral infections, and cancer therapies. The major challenge for the use of nucleic acids in therapy lies in safely delivering these anionic macromolecules to their intended sites of action. At Polyplus-transfection, we develop powerful non-viral vectors to safely deliver nucleic acids in vivo to target a wide range of tissues, through various routes of administrations. Of these reagents, in vivo-jetPEI® is widely acknowledged to deliver nucleic acids in animals; and coherently is selected as the delivery vector of choice in several drug development programs, notably for immunotherapies. As a versatile reagent for in vivo delivery of various and structurally different nucleic acids (plasmid DNA, siRNA, miRNA, mRNA, oligonucleotides), in vivo-jetPEI® is compatible with various modes of injection/administration. To fulfill all the quality requirements associated to its use in Human, Polyplus-transfection® supplies preclinical grade and cGMP grade in vivo-jetPEI® reagents for a growing number of plasmid and oligonucleotide based-preclinical studies and clinical trials.

In vivo-jetPEI, an alternative to viral vectors for nucleic acid-mediated therapies

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.